Krystal Biotech Inc
NASDAQ:KRYS
Products
Krystal Biotech Submits BLA To FDA Seeking Approval Of Dystrophic Epidermolysis Bullosa Treatment
Published: 06/22/2022 11:31 GMT
Krystal Biotech Inc (KRYS) - Krystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-vec for the Treatment of Patients With Dystrophic Epidermolysis Bullosa.
Krystal Biotech Inc - Anticipates Submission of a Marketing Authorization Application With European Medical Agency (ema) in 2h 2022.
Krystal Biotech Inc - Anticipates Submission of a Marketing Authorization Application With European Medical Agency (ema) in 2h 2022.